WO1998012227A1 - Anticorps de recombinaison a chaine unique agissant contre le marqueur gp54 du cancer, composition les contenant et leur mode d'utilisation - Google Patents

Anticorps de recombinaison a chaine unique agissant contre le marqueur gp54 du cancer, composition les contenant et leur mode d'utilisation Download PDF

Info

Publication number
WO1998012227A1
WO1998012227A1 PCT/CA1997/000690 CA9700690W WO9812227A1 WO 1998012227 A1 WO1998012227 A1 WO 1998012227A1 CA 9700690 W CA9700690 W CA 9700690W WO 9812227 A1 WO9812227 A1 WO 9812227A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid sequence
cells
molecule
antibody
Prior art date
Application number
PCT/CA1997/000690
Other languages
English (en)
Inventor
Yves Fradet
André DARVEAU
Original Assignee
Diagnocure Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnocure Inc. filed Critical Diagnocure Inc.
Priority to AU43731/97A priority Critical patent/AU4373197A/en
Publication of WO1998012227A1 publication Critical patent/WO1998012227A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention porte sur de nouvelles molécules d'anticorps à chaîne unique. Les anticorps de départ dont dérivent ces molécules sont le T-16 et le 48-127. Ces anticorps reconnaissent différents épitopes de l'antigène gp54 qui est exprimé à la surface de différentes cellules de carcinome. L'invention porte également sur: la séquence des chaînes légère et lourde et d'une molécule d'anticorps à chaîne unique (scFv) pour chacun des anticorps. Les deux scFv se fixent aux cellules exprimant le gp54, et les complexes d'immunisation sont internalisés par les cellules. L'invention porte également sur des compositions et procédés utilisés à des fins de thérapie et de diagnostic.
PCT/CA1997/000690 1996-09-19 1997-09-19 Anticorps de recombinaison a chaine unique agissant contre le marqueur gp54 du cancer, composition les contenant et leur mode d'utilisation WO1998012227A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43731/97A AU4373197A (en) 1996-09-19 1997-09-19 Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2632096P 1996-09-19 1996-09-19
US60/026,320 1996-09-19

Publications (1)

Publication Number Publication Date
WO1998012227A1 true WO1998012227A1 (fr) 1998-03-26

Family

ID=21831158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000690 WO1998012227A1 (fr) 1996-09-19 1997-09-19 Anticorps de recombinaison a chaine unique agissant contre le marqueur gp54 du cancer, composition les contenant et leur mode d'utilisation

Country Status (2)

Country Link
AU (1) AU4373197A (fr)
WO (1) WO1998012227A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036486A2 (fr) * 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Anticorps
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
WO2003023057A2 (fr) * 2001-09-06 2003-03-20 Adnagen Ag Procede et kit de diagnostic destines a la selection et/ou detection qualitative et/ou quantitative de cellules
WO2003074566A2 (fr) * 2002-03-01 2003-09-12 Immunomedics, Inc. Anticorps rs7
WO2005075647A1 (fr) * 2004-02-06 2005-08-18 Nymox Corporation Anticorps monoclonal anti af-20 humanise
WO2010089782A1 (fr) * 2009-02-05 2010-08-12 Saverio Alberti Anticorps monoclonaux anti-trop-2 et leurs utilisations dans le traitement et le diagnostic de tumeurs
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323806A1 (fr) * 1988-01-05 1989-07-12 Ciba-Geigy Ag Anticorps chimériques
WO1995025167A1 (fr) * 1994-03-17 1995-09-21 Merck Patent Gmbh Fragments d'anticorps a simple chaine anti-egfr et anticorps anti-egfr
WO1995030004A1 (fr) * 1994-04-29 1995-11-09 Mayo Foundation For Medical Education And Research Anticorps monoclonaux favorisant la remyelinisation du systeme nerveux central
WO1995030014A1 (fr) * 1994-05-02 1995-11-09 Ciba-Geigy Ag Proteine a double fonction, sa preparation et son utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323806A1 (fr) * 1988-01-05 1989-07-12 Ciba-Geigy Ag Anticorps chimériques
WO1995025167A1 (fr) * 1994-03-17 1995-09-21 Merck Patent Gmbh Fragments d'anticorps a simple chaine anti-egfr et anticorps anti-egfr
WO1995030004A1 (fr) * 1994-04-29 1995-11-09 Mayo Foundation For Medical Education And Research Anticorps monoclonaux favorisant la remyelinisation du systeme nerveux central
WO1995030014A1 (fr) * 1994-05-02 1995-11-09 Ciba-Geigy Ag Proteine a double fonction, sa preparation et son utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIRD ET AL.: "Single chain antibody variable regions", TIBTECH, vol. 9, 1991, pages 132 - 7, XP002054649 *
DE HARVEN ET AL.: "Antibody Drug Carrier for Immunotherapy of Superficial Bladder Cancer: Ultrastructural Studies", CANCER RE., vol. 52, 1992, pages 3131 - 37, XP002054647 *
EMBL database entry Emrod: Mmiglt522, 20- May-1992 (update), Caton et al.,Antibodiesthat are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions. *
GAUTHIER ET AL.: "Growth-regulated Surface Glycoproteins of Human Bladder Cancer", CANCER RES., vol. 50, 1990, pages 293 - 98, XP002054648 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036486A3 (fr) * 1999-11-18 2002-05-10 Oxford Biomedica Ltd Anticorps
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
WO2001036486A2 (fr) * 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Anticorps
US7507528B2 (en) 2001-09-06 2009-03-24 Adnagen Ag Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
WO2003023057A2 (fr) * 2001-09-06 2003-03-20 Adnagen Ag Procede et kit de diagnostic destines a la selection et/ou detection qualitative et/ou quantitative de cellules
WO2003023057A3 (fr) * 2001-09-06 2003-12-18 Adnagen Ag Procede et kit de diagnostic destines a la selection et/ou detection qualitative et/ou quantitative de cellules
US9272057B2 (en) 2002-02-26 2016-03-01 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2003074566A3 (fr) * 2002-03-01 2004-03-04 Immunomedics Inc Anticorps rs7
US8574575B2 (en) 2002-03-01 2013-11-05 Immunomedics, Inc. RS7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
US7517964B2 (en) 2002-03-01 2009-04-14 Immunomedics, Inc. RS7 antibodies
EP3483183A1 (fr) * 2002-03-01 2019-05-15 Immunomedics, Inc. Immunoconjugués comprenants des anticorps rs7 humanisés
US8084583B2 (en) 2002-03-01 2011-12-27 Immunomedics, Inc. RS7 antibodies
EP2287201A3 (fr) * 2002-03-01 2012-04-04 Immunomedics, Inc. Anticorps RS7
US9849176B2 (en) 2002-03-01 2017-12-26 Immunomedics, Inc. RS7 antibodies
US7238785B2 (en) 2002-03-01 2007-07-03 Immunomedics, Inc. RS7 antibodies
US9999668B2 (en) 2002-03-01 2018-06-19 Immunomedics, Inc. RS7 antibodies
US9833511B2 (en) 2002-03-01 2017-12-05 Immunomedics, Inc. RS7 antibodies
US8758752B2 (en) 2002-03-01 2014-06-24 Immunomedics, Inc. RS7 antibodies
US10179171B2 (en) 2002-03-01 2019-01-15 Immunomedics, Inc. RS7 antibodies
US8992931B2 (en) 2002-03-01 2015-03-31 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2003074566A2 (fr) * 2002-03-01 2003-09-12 Immunomedics, Inc. Anticorps rs7
US8586050B2 (en) 2002-06-14 2013-11-19 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2005075647A1 (fr) * 2004-02-06 2005-08-18 Nymox Corporation Anticorps monoclonal anti af-20 humanise
EA010687B1 (ru) * 2004-02-06 2008-10-30 Нимокс Корпорейшн Гуманизированное антитело
US8715662B2 (en) 2009-02-05 2014-05-06 Oncoxx Biotech S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
AU2009339664B2 (en) * 2009-02-05 2014-12-04 Oncoxx Biotech S.R.L. Anti-Trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
WO2010089782A1 (fr) * 2009-02-05 2010-08-12 Saverio Alberti Anticorps monoclonaux anti-trop-2 et leurs utilisations dans le traitement et le diagnostic de tumeurs
US9670286B2 (en) 2012-08-14 2017-06-06 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9879088B2 (en) 2012-08-14 2018-01-30 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US10662252B2 (en) 2012-08-14 2020-05-26 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
US10436788B2 (en) 2015-04-22 2019-10-08 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells

Also Published As

Publication number Publication date
AU4373197A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
WO2017215585A1 (fr) Anticorps monoclonal anti-cd47 et application correspondante
JP3437580B2 (ja) Ｃｄｒを移植された▲ｉｉｉ▼型抗ｃｅａヒト化マウスモノクローナル抗体
EP1623997B1 (fr) Anticorps de recombinaison et fragments reconnaissant le ganglioside n-glycolyl gm3 et leur utilisation dans le diagnostic et le traitement des tumeurs
JP3194020B2 (ja) 腫瘍抗原特異的抗体、それを含む医薬組成物およびその抗体を産生する細胞系
JP2000511403A (ja) 抗癌胎児抗原抗イディオタイプ抗体のヒト化と腫瘍ワクチンとしての使用及びターゲッティング用途のための使用
RU2204606C2 (ru) Антитело vff-18 и его аналоги
KR100189046B1 (ko) 종양-관련 항원에 대한 모노클로날 항체의 가변성 도메인의 폴리펩타이드
US20070199078A1 (en) Antibody fragments specific for human carcinoembryonic antigen (CEA)
US10208125B2 (en) Anti-mucin 1 binding agents and uses thereof
JPH06506927A (ja) Ｐｅｍムチン縦列繰り返し配列特異性単クローン抗体の最小識別単位
US5976845A (en) Composite antibodies of human subgroup IV light chain capable of binding to TAG-72
JP2022539344A (ja) 抗ｃｅａ抗体及びその応用
WO1998012227A1 (fr) Anticorps de recombinaison a chaine unique agissant contre le marqueur gp54 du cancer, composition les contenant et leur mode d'utilisation
CN113045659B (zh) 抗cd73人源化抗体
JP2024516581A (ja) 抗ヒトｃｄ７３抗体およびその適用
US5645817A (en) Granulocyte-binding antibody constructs, their preparation and use
CN101585880B (zh) 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区
JP3996649B2 (ja) 腫瘍関連抗原に対するモノクローナル抗体、その製造方法およびその使用
EP0618969B1 (fr) Composites de la chaine legere du sous-groupe humain iv aptes a la liaison avec tag-72
CN114685670A (zh) Cldn18.2抗体及其应用
Krishnan et al. Chimerization of mu‐9: A colon‐specific antigen‐p antibody reactive with gastrointestinal carcinomas
US11427646B2 (en) Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
US6641999B1 (en) Probing method for identifying antibodies specific for selected antigens
RU2102479C1 (ru) Химерное моноклональное антитело, взаимодействующее с человеческой плацентарной щелочной фосфатазой, вариабельная область тяжелой гамма-цепи химерного моноклонального антитела, вариабельная область легкой k-цепи химерного моноклонального антитела, фрагмент кднк, кодирующий вариабельную область тяжелой гамма-цепи химерного моноклонального антитела и фрагмент кднк, кодирующий вариабельную область легкой k-цепи химерного моноклонального антитела
TW202200623A (zh) 對炎症性腸病之治療用抗體

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998514108

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA